News | September 05, 2024
Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
e brings over 27+ years of rich pharmaceutical experience
Subscribe To Our Newsletter & Stay Updated
